Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro - Report - MDSpire

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro

  • By

  • Yi-Ping Shih

  • Stephan Drokin

  • Olivia Burke

  • Huayu Huang

  • Amy Leung

  • Marco Bravo-Manriquez

  • Myungkyu Jang

  • Marina S. Syrkina

  • Laura Julian

  • Nelson Sanjuan

  • Eric Tran

  • May 15, 2026

Share

Clinical Report: Rapid Clinical-Scale Manufacturing of TCR-T Cells

Overview

This study presents a novel 10-day protocol for producing TCR-T cells using a cytokine cocktail that enhances early memory and tissue-resident phenotypes. The resulting TCR-T cells demonstrate improved antitumor efficacy in vitro, suggesting a promising approach for adoptive cell therapy in solid tumors.

Background

Adoptive cell therapy (ACT) using TCR-engineered T cells has shown potential in treating solid tumors, yet the effectiveness is influenced by the T cell phenotypes employed. T cells with younger, less differentiated characteristics are associated with better antitumor responses, highlighting the need for efficient production methods that enhance these phenotypes for therapeutic use.

Data Highlights

ParameterCKT TCR-T CellsIL-2 TCR-T Cells
Cell Yield3.30 x 10^96.15 x 10^9
Early Memory T CellsIncreasedDecreased
Tissue-Resident T CellsEnhancedReduced
IFN-γ ProductionIncreasedStandard
CytotoxicityImprovedStandard

Key Findings

  • The cytokine cocktail (CKT) includes IL-2, IL-7, IL-15, and TGF-β, enhancing TCR-T cell production.
  • CKT TCR-T cells showed a higher prevalence of early memory and tissue-resident phenotypes compared to IL-2 TCR-T cells.
  • CKT TCR-T cells exhibited increased expression of 4-1BB and enhanced production of IFN-γ, TNF, and granzyme B.
  • In vitro cytotoxicity against pancreatic and colorectal cancer cell lines was significantly improved with CKT TCR-T cells.
  • The clinical-scale production process yielded comparable phenotypic and functional characteristics to small-scale experiments.

Clinical Implications

The rapid production of TCR-T cells with enhanced memory and tissue-resident characteristics may improve the efficacy of adoptive cell therapy for solid tumors. This methodology could potentially shorten the time from cell collection to therapy administration, addressing a critical bottleneck in current treatment protocols.

Conclusion

The innovative 10-day production protocol for TCR-T cells using a specific cytokine cocktail demonstrates significant improvements in T cell phenotypes and antitumor efficacy, offering a promising advancement in the field of adoptive cell therapy.

Related Resources & Content

  1. Blood Cancer Journal, 2022 -- Rapid Production of a Novel Anti-CD19 CAR-T Therapy for B-cell Acute Lymphoblastic Leukemia: Initial Human Clinical Trial Results
  2. Bone Marrow Transplantation, 2024 -- Evaluating Release Criteria for Autologous CAR T Cell Products: Insights from the UNITC Consortium
  3. the medicine maker, 2026 -- CRISPR Enables In Vivo CAR T Cell Production
  4. FDA, 2024 -- FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma
  5. SITC, 2024 -- Society for Immunotherapy of Cancer clinical practice guideline on immune effector cell-related adverse events
  6. The ASCO Post — New Data on ALK Inhibitors and CAR T-Cell Therapies
  7. Advances in IL-7 Research on Tumour Therapy
  8. FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma | FDA
  9. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events | Journal for ImmunoTherapy of Cancer

Original Source(s)

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro

  • by Yi-Ping Shih, Stephan Drokin, Olivia Burke, Huayu Huang, Amy Leung, Marco Bravo-Manriquez, Myungkyu Jang, Marina S. Syrkina, Laura Julian, Nelson Sanjuan, Eric Tran

  • May 15, 2026

Related Content

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures

Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...